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Abstract 
Late normal tissue toxicity varies widely between patients and limits breast radiotherapy 
dose. Here we aimed to determine its relationship to DNA damage responses of fibroblast 
cultures from individual patients. Thirty-five breast cancer patients, with minimal or 
marked breast changes after breast-conserving therapy consented to receive a 4Gy test 
irradiation to a small skin field of the left buttock and have punch biopsies taken from 
irradiated and unirradiated skin. Early-passage fibroblast cultures were established by 
outgrowth and irradiated in vitro with 0 or 4Gy. 53BP1 foci, p53 and p21/CDKN1A were 
detected by immunofluorescence microscopy. Residual 53BP1 foci counts 24h after in 
vitro irradiation were significantly higher in fibroblasts from RT-sensitive versus RT-
resistant patients. Furthermore, significantly larger fractions of p53- but not 
p21/CDKN1A-positive fibroblasts were found in cultures from RT-sensitive patients 
without in vitro irradiation, and 2h and 6d post-irradiation. Exploratory analysis showed a 
stronger p53 response 2h after irradiation of fibroblasts established from patients with 
severe reaction. These results associate the radiation response of fibroblasts with late 
reaction of the breast after RT and suggest a correlation with severity.   
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1. Introduction 
In women treated with radiotherapy for primary breast cancer after local excision of the 
primary tumour, breast shrinkage, hardness and pain are common consequences [1-3]. A 
study of telangiectasia by Turesson [4] showed considerable variation in severity between 
patients treated under the same conditions. Analysis of these data suggested that if all 
known extrinsic factors are controlled, those intrinsic to the individual may account for 
≥80% of clinical complication risk [5, 6]. 
Radiation damage to fibroblasts is considered to be a key factor in the pathogenic 
pathway leading to fibrosis. However, although initial results suggested that intrinsic 
radiosensitivity of fibroblasts isolated from individual patients may predict the patients’ 
risk of developing fibrosis after radiotherapy [7-10], correlations were weak and 
subsequent studies did not confirm a significant correlation [10-16]. This has been 
explained by the hypothesis that in vitro cellular responses correlate poorly with in vivo 
responses due to the modifying influence of tissue environment [17-19]. The number of 
residual radiation-induced DNA double-strand breaks (DSBs) has received less attention. 
An early study reported a correlation between the severity of fibrosis and the fraction of 
DNA released by pulse-field gel electrophoresis (PFGE) after irradiation of early-passage 
fibroblast strains in vitro [20], but this was not confirmed in a validation cohort [21] or in 
a different study using constant-field gel electrophoresis [11]. However, very high doses 
(up to 150Gy) were used to detect residual DSBs by this technique. Since the latter study 
found significantly higher numbers of lethal chromosome aberrations in lymphocytes 
irradiated with a more moderate dose of 6Gy from patients with severe late reaction, 
there is still a powerful argument for exploring ways of measuring cellular responses to 
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relevant doses of radiotherapy ex vivo using the much more sensitive technique of DNA 
DSB repair foci.  
The purpose of the present study was to explore the relationship between the risk of 
developing late breast shrinkage/hardening after radiotherapy and the DNA damage 
response in cultures of dermal fibroblasts from individual patients, established from 
unirradiated skin and skin given a test irradiation dose in vivo..  
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2. Materials and methods 
Patients, in vivo irradiation, and establishment of fibroblast cultures  
The manner of patient selection had been previously described [22]. Briefly, patients in 
this study had taken part in two randomised clinical trials organised by the Institute of 
Cancer Research and The Royal Marsden NHS Foundation Trust, comparing 
fractionation schemes and irradiation techniques, respectively, with prospective annual 
clinical assessments of late adverse effects using standard proformas [23, 24]. Thirty-five 
breast cancer patients who showed no evidence of recurrent cancer 3-10 years after 
surgical excision of the tumour and post-operative radiotherapy to the whole breast 
consented to a test irradiation and subsequent biopsies of the skin 24h and 12 weeks after 
irradiation. Ethical approval for the study was obtained from the Royal Marsden NHS 
Research Ethics Committee, and written consent was obtained from the patients prior to 
participation.  
The study group comprised of clinically RT-sensitive patients (n=20) and RT-resistant 
(n=15) patients based on the severity of their reactions versus known clinical risk factors 
and was enriched for highly sensitive patients. Follow up was 3-24 years for RT-sensitive 
(median 11 years) and 11-24 years (median 13 years) for RT-resistant patients. Patient 
characteristics and treatment parameters are shown in Table 1. Overall, RT-sensitive 
patients had larger surgical deficits but received less tumour-bed boost irradiation and 
chemotherapy. One RT-sensitive patient withdrew consent prior to the 12-week biopsies, 
leaving 34 patients for analysis in the present study. For exploratory analysis, RT-
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sensitive patients were further subdivided into two subgroups of moderate risk (n=9) and 
high risk (severe reaction, n=10).  
Test irradiation of the skin was performed as previously described [25]. Patients received 
a single 4Gy radiation dose to a small area of skin on the upper outer quadrant of the 
buttock. A 6MeV electron beam from a radiotherapy linear accelerator exposed an area of 
skin 4×2cm, and an 8mm perspex build-up filter was used to ensure dose homogeneity 
throughout the epidermis and dermis.  
Twelve weeks following irradiation, four 4mm punch biopsies were obtained from both 
irradiated and contralateral unirradiated skin. Two of the replicate biopsies were used to 
establish primary fibroblast cultures for the present study. The skin samples were shipped 
to Mannheim in serum-free basal medium at ambient temperature where they were cut 
into smaller pieces, placed in T25 tissue culture flasks and left to adhere for 2h. After 
attachment, cells were incubated with cell culture medium (Gibco AmnioMax C100 basal 
medium; Life Technologies GmbH, Darmstadt, Germany) supplemented with 7.5% 
AmnioMax C100 supplement (Life Technologies), 7.5% fetal bovine serum (FBS; 
Biochrom AG, Berlin), 2mM glutamine, and penicillin/streptomycin. Primary cultures 
established by outgrowth were expanded by passaging twice and cryopreserved in the 3rd 
passage. For the present in vitro experiments, frozen vials of fibroblasts in passage 3 were 
thawed, expanded by passaging twice and used for the present experiments in passage 5.  
Fibroblast cultures were successfully established from all patients and showed similar 
levels of the human proliferation marker Ki-67 (MKI67) in cultures established from skin 
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irradiated in vivo (clinically) 12 weeks earlier as well as cultures from unirradiated skin 
(Supplementary Figure S1). 
The study design is shown in Figure 1. Residual 53BP1 (TP53BP1) foci were determined 
24h after in vitro irradiation of fibroblasts established from unirradiated skin biopsies 
taken at the 12-week time point. Furthermore, 53BP1 foci were determined in 
unirradiated parallel fibroblast cultures established from biopsies taken from unirradiated 
and in vivo irradiated skin 12 weeks after irradiation. p53 (TP53) and p21/CDKN1A were 
determined 2h, 2d and 6d after irradiation in vitro and in unirradiated cultures from 
unirradiated and in vivo (clinically) irradiated skin (in parallel with day 2 samples). 
Irradiation and immunofluorescence microscopy of fibroblasts in vitro 
5×103 cells were seeded per well in chamber slides (BD Falcon), incubated overnight and 
irradiated the next day with 4Gy of 6MV X-rays from a linear accelerator (Synergy, 
Elekta, Crawley, UK) at a dose rate of 6 Gy/min. After irradiation, cells were incubated 
at 37°C under CO2 and fixed at different time points. The cells were rinsed with PBS, 
fixed for 15 minutes at room temperature with 3.7% paraformaldehyde and permeabilised 
for 5 minutes with 0.5% Triton X-100 in PBS at 4oC. Slides for detection of residual 
γH2AX and 53BP1 foci 24h after irradiation were shipped in PBS to the PHE Centre for 
Radiation, Chemical and Environmental Hazards, Chilton, UK and processed as 
previously described [26]. For detection of Ki-67, p53 and p21/CDKN1A, fibroblasts 
were treated and fixed at 2h, 2d and 6d after irradiation using 3.7% formaldehyde in PBS 
with 0.2% Triton X-100 (PBST) for 10 min. Details of antibodies and staining protocols 
are given in Supplementary Material. 
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Statistical analysis 
Differences between fibroblasts from RT-sensitive and RT-resistant patients were 
analysed by the non-parametric Wilcoxon/Mann-Whitney test. Correlations were 
analysed by linear regression or the non-parametric Spearman's ρ rank correlation test. A 
linear model was used to test the effect of measured parameters on clinical 
radiosensitivity. All tests were performed using the JMP.v11 Statistical Discovery 
software package (SAS Institute GmbH, Boeblingen, Germany). P <0.05 was considered 
statistically significant for the planned analysis, and P<0.01 for exploratory analysis. 
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3. Results 
Quantification of residual DSB in skin fibroblasts in vitro 
The mean number of residual 53BP1 foci per cell in the nuclei 24h after in vitro 
irradiation of fibroblasts established from unirradiated skin was significantly increased 
over the background. The median for all patients was 2.07 [quartiles: 1.73; 2.46] for 4 Gy 
versus 0.64 [quartiles: 0.51; 0.83] for 0 Gy (P<0.0001). We compared these values with 
the residual and background numbers of foci in fibroblasts scored in situ in sections of 
skin biopsies 24h after the clinical test irradiation of the skin in vivo (Somaiah et al., 
submitted). Overall, the two sets of values for irradiation with 4 Gy in vitro or in vivo, 
and their corresponding background values without irradiation, compared quite well 
although the difference in mean foci numbers between irradiated and unirradiated cells 
was larger in situ (Supplementary Figure S2). However, within each dose level no 
correlation between the numbers of foci scored in fibroblast cultures and in skin sections 
from individual patients was observed.  
Because foci levels with and without irradiation might be informative in their own right, 
it was decided to analyse the data without background subtraction. Residual foci levels 
after in vitro irradiation of fibroblasts established from unirradiated skin were 
significantly higher (P=0.007, n=34) in cultures from RT-sensitive than from RT-
resistant patients (Figure 2a). In contrast, no significant difference was seen either for 
unirradiated fibroblast cultures established from unirradiated skin (P=0.27, n=31) or from 
skin irradiated in vivo with a test dose of 4 Gy 12 weeks earlier (P=0.18, n=34). A 
moderate, positive correlation (linear regression: R2=0.34; Spearman's ρ=0.60, P=0.0004; 
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n=31) was observed between residual 53BP1 foci and the background levels in the 
unirradiated fibroblast cultures from individual patients (Figure 2b). However, 
subtraction of the background levels for individual patients did not enhance the difference 
between RT-sensitive and RT-resistant patients (not shown).  
It was noted that the variance of residual 53BP1 foci was 5.5-fold larger in the RT-
sensitive than in the RT-resistant group (0.908 and 0.166, respectively). To explore 
whether the higher mean number of residual 53BP1 foci and larger variance might be 
associated with the degree of severity, the correlation with risk score was tested. A 
significant correlation with severity (ρ=0.45, P=0.008, n=34) was observed after in vitro 
irradiation (Supplementary Figure S3b). However, a trend for a correlation (ρ=0.33, 
P=0.07, n=31 and ρ=0.35, P=0.04, n=34, respectively) was also observed in unirradiated 
cultures established from unirradiated and in vivo test-irradiated skin (Supplementary 
Figure S3a,c). In fact the background numbers were very similar in the two cultures and 
showed an increase in samples from patients with severe reaction (risk group 2). 
Therefore, it seemed justified to treat these cultures as independent determinations of the 
background 53BP1 foci. When the two cultures were analysed together, the correlation 
with severity was highly significant (ρ=0.33, P=0.007, n=34+31). After background 
subtraction, the correlation of residual foci after in vitro irradiation showed only a trend 
(ρ=0.35, P=0.05, n=31) (Supplementary Figure S3d). Taken together, these data suggest 
that the higher numbers of 53BP1 foci in RT-sensitive patients with severe reaction may 
be associated with higher background levels before irradiation. 
Radiation response markers p53 and p21/CDKN1A 
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Irradiation of fibroblasts in vitro increased the fraction of cells scoring positive for p53 
within 2h (Figure 3a). p53 stayed at a similar level on day 2 but decreased on day 6 to a 
level slightly but not significantly higher than the basal level without irradiation. The p53 
level in cultures established from in vivo irradiated skin was not significantly increased 
compared with the basal level in cultures from unirradiated skin (P=0.62). The fraction of 
p53-positive fibroblasts was significantly higher in cultures from RT-sensitive patients 
compared with RT-resistant patients before and 2h after in vitro irradiation, and was 
marginally significant on day 6 (Figure 3b). The overall difference in p53 levels between 
RT-sensitive versus RT-resistant patients for all conditions was highly significant 
(P=0.0013). When basal p53 levels (0 Gy in vitro) in cultures from unirradiated and in 
vivo irradiated skin were analysed together, the basal level in fibroblasts from RT-
sensitive patients was significantly increased (P=0.009, n=34+34).  
The variance of p53 levels in unirradiated fibroblasts (0 Gy in vitro) from unirradiated 
skin was 3.0-fold larger in the RT-sensitive than the RT-resistant group (0.00448 and 
0.00147, respectively) and 5.2-fold larger 2h post-irradiation (0.0617 and 0.0119, 
respectively). The latter was related to an early, strong induction of p53 in fibroblasts 
from RT-sensitive patients with severe reaction compared to RT-resistant patients or RT-
sensitive patients with more moderate risk. Whereas the basal level of p53-positive cells 
in unirradiated fibroblast cultures was increased for RT-sensitive versus -resistant 
patients, p53 in fibroblasts from patients with severe reaction (risk group 2) showed a 
strong, early increase 2h after irradiation. By contrast, fibroblasts from patients with 
moderate risk score (risk group 1) reached the highest value at 2d post-irradiation similar 
to fibroblasts from RT-resistant patients (Figure 3c).  
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The fraction of cells scoring positive for p21/CDKN1A (a p53 downstream target) was 
unchanged 2h after irradiation but was significantly increased at 2d and 6d whereas no 
significant increase was observed in fibroblasts from in vivo irradiated skin (Figure 4a). 
However, no significant difference in p21/CDKN1A between fibroblasts from sensitive 
and resistant patients was detected in any of the groups (Figure 4b). 
The increased basal p53 level for RT-sensitive patients was observed in both risk groups 
(1 and 2) whereas the positive correlation of early p53 response with clinical severity 
(ρ=0.47, P=0.005, n=34) was due to patients with severe reaction only (Supplementary 
Figure S4a,b). Furthermore, early upregulation of the downstream target p21/CDKN1A 
at 2h was indicated for the RT-sensitive patients with severe reaction (Supplementary 
Figure S4d). 
A weak correlation (ρ=0.38; P=0.03) was observed between the in vitro parameters 
residual 53BP1 foci (4Gy, 24h) and p53 response (4Gy, 2h), whereas the correlation of 
residual 53BP1 with basal p53 (0 Gy) showed a trend (ρ=0.31; P=0.08). However, in a 
linear model, only residual 53BP1 foci and basal p53 were predictive of RT-sensitive 
versus RT-resistant patients (P= 0.010 and P=0.03, respectively) with a weak trend for an 
interaction (P=0.16). With respect to severity (risk score), predictive modelling showed a 
strong trend (P=0.04) for early p53 response (2h) and a weak trend (P=0.18) for 
background 53BP1 foci (0Gy) with no significant interaction (P=0.58). In fact, early p53 
response alone was a more significant predictor of severity (P=0.0014). These results 
reflect that residual 53BP1 foci and basal p53 levels were increased for both RT-sensitive 
risk groups (1 and 2) while only fibroblasts from RT-sensitive patients with severe 
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reaction (risk group 2) showed a strong early increase of p53. Taken together, this 
indicates that 53BP1 and p53 may be partly independent predictors. 
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4. Discussion 
The present study tested the relation between individual patients' late normal tissue 
reaction (changes in breast appearance) after whole-breast radiotherapy and the radiation 
response of their individual fibroblast cultures in vitro. The major findings for RT-
sensitive versus RT-resistant patients are (I) a higher number of residual DSBs after in 
vitro irradiation and (II) an increased fraction of p53 positive cell without in vitro 
irradiation. These results associate the radiation response of fibroblasts, i.e. the functional 
cells of connective tissue, with the development of radiation-induced breast 
shrinkage/hardening. Further exploratory analysis showed a vigorous, early p53 response 
to radiation in the subgroup of patients who developed severe reaction despite few 
identified risk factors. Since the RT-sensitive group was enriched in such patients, the 
association with radiation response may be important only in a minority of the patients.  
The study design involved a test irradiation to previously unirradiated skin in order to 
determine residual and longer-term damage. Residual DSBs scored in situ will be 
presented elsewhere (Somaiah et al., submitted). However, the cultures established 12 
weeks after the test irradiation from in vivo irradiated and unirradiated skin were rather 
similar with respect to the proliferation marker Ki-67, background 53BP1 foci, and basal 
p53 levels. Therefore, the fibroblasts growing out from these skin biopsies appeared to 
have largely recovered from radiation damage. 
Radiation-induced oxidative stress is observed in tissue not only during irradiation but 
may persist many weeks after irradiation, and may even affect tissues outside the 
irradiated field via non-targeted effects [27, 28]. These reactions are considered to be 
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propagated by NF-κB-mediated cytokine production and inflammatory reactions [29], 
leading to further oxidative DNA damage [30, 31]. Thus the immune system plays an 
important role in maintaining a vicious circle involving persistent activation of the DNA 
damage response [32]. Residual 53BP1 foci mark unrepaired DSBs after irradiation. On 
the other hand, increased p53 levels without irradiation suggest an increased basal stress 
level which might be caused by systemic or genetic factors. Support for a patient-related 
factor (systemic or genetic) comes from a previous study on lymphocytes from seven RT-
sensitive and seven RT-resistant patients belonging to the present cohort, which showed 
significantly increased residual 53BP1 foci 24h after irradiation in vitro [25]. 
Furthermore, chromosome aberrations were significantly increased, and residual 53BP1 
foci correlated with deletion type of aberrations indicating a deficiency in DSB repair. 
Together with the findings from the present study, this suggests a hypothesis in which a 
defect in the p53 stress response pathway may contribute to late reaction in RT-sensitive 
patients, possibly via increased misrepair and, genomic instability leading to premature 
terminal differentiation of fibroblasts. Thus, it is well established from work with tumour 
cells, that overexpression of p53 frequently represents a defect in p53 function. However, 
the partial independence of basal p53 levels and residual 53BP1 foci may indicate that 
unrepaired DSBs and genomic instability may be caused by a DSB repair deficiency in 
some patients. 
For all significant endpoints, the increased levels in RT-sensitive compared with RT-
resistant patients were associated with a three to five-fold larger variance. Thus only a 
proportion of RT-sensitive patients showed increased levels of 53BP1 foci or p53 while 
the rest were in the same range as RT-resistant patients (Supplementary Figures S3 and 
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S4). Exploratory analysis suggested a correlation with severity of late reaction supporting 
the hypothesis that subgroups of patients characterised by different mechanisms of late 
reaction may exist [Herskind et al., in revision]. Bioinformatic analysis can be used to 
identify genetic factors of clinical and cellular radiation responses [33] and thus 
combining the two approaches might help characterise pathways associated with different 
subgroups [Herskind et al., in revision]. 
In contrast with the present work, recent studies on the relation between DSB induction 
and repair by moderate doses in vitro and patients' normal-tissue reaction after 
radiotherapy have been performed with lymphocytes. Expression of γH2AX protein 
measured by flow cytometry (FACS) showed higher sustained levels in over-reactors 
with different acute or chronic toxicity after RT for different tumours [34] while a similar 
study of mixed endpoints after prostate RT showed no significant difference [35]. Three 
studies on late reaction after breast [22, 36] or prostate RT [37] showed significant 
associations with residual DSBs while two studies of late toxicity in breast [38] or 
various RT patients [39] were not significant. Recent large studies (n=54 to 89) on early 
toxicity to RT showed a clearer picture with significant associations of DSB repair in 
breast [40] and various mixed cancers [41-43]. This supports the hypothesis that residual 
DSBs are associated with the risk of normal tissue reaction to RT although the 
association may be influenced by the clinical endpoint and cell type studied. 
Upon induction of cell stress by DNA damaging agents such as ionising radiation, 
phosphorylation processes lead to stabilisation of p53 by dissociation from the E3 
ubiquitin-protein ligase MDM2 which normally inactivates p53 and targets it for 
cytoplasmic translocation and proteasomal degradation. Stabilised p53 undergoes post-
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translational modification, nuclear translocation and tetramerisation to act as a 
transcription factor, and has multiple functions including induction of cell-cycle arrest in 
G1 via p21/CDKN1A, DNA repair, and apoptosis [44-46]. Recent studies have 
emphasised the role of pulsed p53 expression in response to different levels of DNA 
damage suggesting that short pulses lead to transient cell-cycle arrest while sustained p53 
signalling leads to apoptosis or permanent cell-cycle arrest [47, 48]. Furthermore, p53 
may induce or suppress differentiation in different cell types [49].  
Fibroblasts do not normally undergo radiation-induced apoptosis [50]. Instead they arrest 
permanently in a state which is sometimes termed senescent but is more appropriately 
described as premature differentiation since the cells stay metabolically active with 
increased synthesis and deposition of extracellular matrix proteins [51-54]. The present 
results suggest that p53 is increased in RT-sensitive patients even without irradiation and 
may be sustained at a higher level at 6d after in vitro irradiation. This would be consistent 
with a higher propensity to undergo permanent cell-cycle arrest leading to premature 
differentiation or senescence. In addition, patients with more severe reaction showed 
strong early upregulation of p53 suggesting a more vigorous response of transient cell-
cycle arrest and DNA repair. However, expression of the endogenous cdk inhibitor 
p21/CDKN1A which is a major transcriptional target of p53 and part of the stress-
induced G1/S cell-cycle checkpoint, was not associated with late reaction. Instead, we 
speculate that another p53 transcriptional target GADD45, which plays important roles in 
genomic stability and differentiation [55-57], might be involved, in which case it might 
target the G2/M rather than the G1/S checkpoint [58]. 
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In conclusion, we have found a small but significant increase in the number of residual 
DSBs and a consistently higher fraction of p53-positive cells without irradiation, as well 
as 2h and 6d after in vitro irradiation of fibroblasts from RT-sensitive versus RT-resistant 
patients. This establishes an association between the radiation response of fibroblasts and 
late reaction of the breast after RT. Exploratory analysis of ranked risk groups suggested 
that vigorous, early upregulation of p53 is prominent in a small subgroup of patients with 
severe reaction. Residual 53BP1 foci at 24h and basal p53 levels or p53 at 2h post-
irradiation showed only weak correlations, and prospective analysis suggested they may 
be independent markers, possibly representing different aspects of the radiation response. 
Although the present study does not allow prediction of RT-sensitive patients, the 
identification of rare patients at risk for severe reaction after radiotherapy might be 
feasible based on the early p53 response. However, validation and further studies on 
mechanisms and genetic factors will be required to establish a reliable test and search for 
additional surrogate markers. 
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Figure legends 
Figure 1. Experimental design of the present study. Residual foci were also scored 
in sections of skin biopsies 24h after irradiation in vivo and will be presented elsewhere 
(Somaiah et al. submitted). 
Figure 2. (a) Comparison of 53BP1 foci in fibroblast cultures from RT-sensitive and 
RT-resistant patients. Cells established from irradiated or unirradiated skin 12 weeks after 
the in vivo test-irradiation were fixed 24h after in vitro irradiation with 0 Gy or 4 Gy. . 
The mean number of residual 53BP foci 24h after in vitro irradiation was significantly 
increased for RT-sensitive versus -resistant patients (P=0.007, n=34). Background levels 
of 53BP1 in the cultures established from irradiated and unirradiated skin from the same 
patients did not differ significantly (pairwise non-parametric test: P=0.71, n=14, and 
P=0.22, n=17 for RT-resistant and -sensitive patients, respectively). Mean values and 
standard errors are shown. n=19 (RT-sensitive) and n=15 (RT-resistant) except for 0Gy 
fibroblasts from unirradiated skin (n= 17, and n=14, respectively). (b) For cultures from 
unirradiated skin, the mean number of residual 53BP1 foci per fibroblast 24h after in 
vitro irradiation correlated with the background numbers in unirradiated cells (R2=0.34; 
Spearman's ρ=0.60, p=0.0004; n=31, samples from RT-sensitive and RT-resistant 
patients were included). 
Figure 3. (a) The fraction of p53 positive cells was significantly increased 2h 
(P=0.012) and 2d (P=0.0001) after in vitro irradiation of fibroblast cultures (n=34) from 
unirradiated skin while a trend was observed at 6d (P=0.10). No significant increase 
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(P=0.62) was observed for unirradiated cultures of fibroblasts established from in vivo 
irradiated skin. Box plot shows median, and 25/75% and 10/90% percentiles. P-values 
were calculated by Wilcoxon comparison of each pair. (b) Increased positive fractions in 
cultures from RT-sensitive relative versus RT-resistant patients. P-values were calculated 
by the Wilcoxon/Mann-Whitney test. Mean values and standard errors are shown. (c) 
Kinetics of radiation-induced p53 induction for different risk groups (0: RT-resistant, 
n=15; 1: RT-sensitive with moderate risk, n=9; 2: RT-sensitive with severe reaction (high 
risk, n=10). Mean values and standard errors are shown.  
Figure 4. (a) The fraction of p21 positive cells was significantly increased 2d and 6d 
(P<0.0001) after in vitro irradiation of fibroblast cultures (n=34) from unirradiated skin 
but not at 2h (P=0.61). No significant increase (P=0.71) was observed for unirradiated 
cultures of fibroblasts established from in vivo irradiated skin. Box plot shows median, 
and 25/75% and 10/90% percentiles. P-values were calculated by Wilcoxon comparison 
of each pair. (b) No significant differences between positive fractions in cultures from 
RT-sensitive and RT-resistant patients (Wilcoxon/Mann-Whitney test; mean values and 
standard errors are shown). 
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Table 1. Patient characteristics and treatment parameters1. Radiotherapy (RT) dose to the whole 
breast, RT technique (3D or standard 2D wedge), tumour bed boost, surgical deficit, and axillary 
treatment, were significant risk factors. 
 
RT-sensitive RT-resistant 
 
Patients (n=35) 
 
202 
 
15 
 
Median age, years (range) 
 
70 (52-83) 
 
68 (54-78) 
 
Median follow-up, years (range) 
 
11 (3-24) 
 
13 (11-24) 
 
Mean breast RT dose, Gy* 
 
50.0 
 
50.8 
 
Dosimetry techniques 
3D 
2D 
 
 
10 
10 
 
 
3 
12 
 
Number patients prescribed boost dose 
 
15 
 
15 
 
Mean tumour bed boost dose, Gy 
 
9.8 
 
12.7 
 
Breast size 
Small 
Medium 
Large 
 
 
8 
10 
2 
 
 
2 
13 
0 
   
 
Surgical deficit 
Small 
Medium  
Large 
 
 
8 
8 
4 (1 mastectomy3) 
 
 
11 
3 
1 
 
Axillary treatment 
 
15 
 
11 
 
Tamoxifen 
 
14 
 
12 
 
Chemotherapy 
 
8 
 
15 
 
 
1 Equivalent total dose given in 2 Gy fractions assuming α/β=3 Gy 
2
 One RT-sensitive patient (risk score 1) withdrew consent before biopsies were taken at 12 
weeks. 
3 Patient had mastectomy & reconstruction before RT; this was the only patient with <5yr follow 
up 
 
  
29 
 
 
Figure 1 
 
  
30 
 
 
 
Figure 2 
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Figure 3 
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Figure 4 
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Nuta et al., Supplementary Materials and Methods 
 
Immunostaining for fluorescence microscopy 
Upon arrival at the PHE, Chilton, samples for γH2AX and 53BP1 staining were blocked 
for 30 minutes with PBS containing 3% w/v BSA Fraction V (Sigma-Aldrich, Dorset, 
UK) and incubated with primary antibody diluted in PBS + 2% FBS for 1 hour at room 
temperature. Cells were then washed three times with PBS + 2% FBS , incubated with 
secondary antibody and DAPI (4´,6-diamidino-2-phenylindole) diluted in PBS + 2% FBS 
for 1 hour at room temperature in the dark, followed by three further washes with PBS + 
2% FBS. After drying, slides were mounted using Vectashield and visualized using a 
Nikon Eclipse TE200 epifluorescence microscope. Co-localizing γH2AX and 53BP1 foci 
were scored and a minimum of 50 cells were scored for each patient. The following 
antibodies were used: anti-53BP1 (mab3802, Millipore, Watford, UK, 1:400 and 
ab36823, Abcam, Cambridge, UK, 1:400), anti-γH2AX (05-636, Millipore, 1:200 and 
ab26350, Abcam, 1:500). Appropriate secondary antibodies were conjugated with Alexa-
Fluor 488 (Invitrogen, Paisley, UK, 1:200) and TRITC (Tetramethylrhodamine-5-(and-
6)-isothiocyanate, Jackson Immunoresearch, Suffolk, UK, 1:200). 
Samples for detection of Ki-67, p53, and p21, were processed at the UMM in Mannheim. 
After rinsing, cells were incubated with 1% BSA in PBST for 10 min and incubated with 
primary antibody in PBST for 45 min. The following primary antibodies were used: 
rabbit polyclonal anti-Ki-67 (Abcam ab15580, 1:500), rabbit polyclonal anti-p53 (Cell 
Signaling #9282, 1: 300), mouse monoclonal anti-p21/CDKN1A (Cell Signaling #2946, 
1:300). Cells were washed 3×5 min with PBST and incubated with secondary FITC-
conjugated antibody (goat anti-rabbit IgG, Millipore AP307F or goat anti-mouse-IgG, 
Santa Cruz, 1:500). 
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